New service ensures rapid delivery of small volume clinical trial materials, solving a critical bottleneck in drug ...

Aversa Fentanyl holds the potential to become the world’s first abuse-deterrent opioid patch.

Biosimilars sales were $201.5 million, up 7% driven by Benepali, with sales of $125 million, up 16%. LEQEMBI global in-market sales in the quarter were approximately $87 million, including U.S.

New 5mg tablet offers the same established efficacy and safety as the Evrysdi oral solution for individuals living with spinal muscular atrophy.

Sygnature Discovery has appointed Fraser McIntosh as Vice President, In Vivo Pharmacology. Fraser will lead the company’s in vivo drug discovery operations worldwide.